Type 2 Diabetes medication - Which One is Right Here?

Researchers from the Department of Medicine are looking for people with type 2 diabetes who are taking one or two different tablets for diabetes, but not insulin.

What's involved?

This is an 8-month randomised crossover study of vildagliptin and pioglitazone designed to investigate personalised medicine in patients with type 2 diabetes, to see whether we can predict who will respond most, in terms of glucose lowering, to vildagliptin or pioglitazone based on clinical characteristics, biochemistry as well as genetics.

You will be asked to take one additional diabetes tablet daily (vildagliptin or pioglitazone) for 4 months then swap to the other medication for 4 months. We will analyse routine medical information, blood markers including genetics, to study if we can predict your response to these diabetes medications.

Eligibility criteria

We hope to recruit 300 participants with Type 2 diabetes who are:

  • Age 18-80
  • On either metformin or sulfonylurea (such as gliclazide) alone, or on both medications (stable doses for 3 months)
  • No current or past insulin use in 3 months
  • HBA1c >58 but <=110.
  • Never been on pioglitazone or vildagliptin


If you think you are potentially eligible for this study, or if you are considering starting vildagliptin as add-on therapy, please read the participant information sheet and consent form before contacting the researchers using the details below:

Dr Rinki Murphy, Dr Ryan Yeu and Dr Rebecca Brandon
Email: T2Dmed@auckland.ac.nz
Phone: 0272617559

This study has been approved by the Health and Disability Ethics Committees (HDEC) reference number 18/STH/242